News

The election is right around the corner and there’s a lot of information to absorb. That is why the National Hemophilia Foundation…

A coalition of 33 organizations, including the National Hemophilia Foundation, representing millions of people with pre-existing conditions launched an unprecedented effort today…

Feeling disconnected from knowledge about women’s health and research? Get WIRED with the Hemophilia Federation of America (HFA) is seeking women with bleeding…

This summer’s Virtual Bleeding Disorders Conference (BDC) featured a pair of excellent public health symposiums, which were developed through an inspired collaboration…

The purpose of the study is to evaluate the efficacy and safety of this investigational gene therapy in patients with moderately severe…

This commentary was authored by six individuals with severe hemophilia, all of whom have worked to achieve better health outcomes for patients…

The recent news about the passing of United State Supreme Court Justice Ruth Bader Ginsburg and nomination of Judge Amy Coney Barrett…

NHF and HFA have been provided the following statement from CSL Behring. The statement says, in part: “Ferring Pharmaceuticals Inc. initiated a voluntary,…

The Milwaukee Unified Emergency Operations Center continues to put out up-to-date information for the citizens of Milwaukee County. This information is also…

The National Hemophilia Foundation (NHF) is working with the bleeding disorders community to envision our future for the next decade, and they…

Gene therapy for hemophilia remains a very active area of research, although it may take longer than expected. To discuss this, join…

The NHF is saddened by the loss of life and destruction of communities due to catastrophic fires in the west and a…

A recent commentary published in the journal Haemophilia, posits that while clinical trials for hemophilia gene therapy approach conclusion, there remain significant unanswered…

Sanofi recently announced results from their phase 1/2a EXTEN-A trial for their investigational therapy BIVV001, which were published in the New England Journal…

CSL Behring recently announced that they are discontinuing Mononine®, the company’s human plasma-derived factor therapy indicated for the prevention and control of…

The National Hemophilia Foundation will be holding our quarterly Board of Directors meeting on Saturday, October 10th at 9:00 AM EDT. The Board…

In the fall of last year Genentech reported that during a routine examination of batches of Hemlibra®, they found translucent particles composed…

The National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA) continue to follow up on issues arising from the recent recall of Stimate (desmopressin)…

The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) issued two new documents, which were adopted by NHF’s Board of…

by: Debbie de la Riva The collective pursuit to control the spread of coronavirus has resulted in an enormous challenge for the…

NHF’s Bleeding Disorders Conference was fully virtual this year and included more than 50 sessions. Those sessions are all available on-demand until…

Last month, BioMarin learned that approval for their investigational hemophilia A gene therapy was not forthcoming but would in fact be delayed…

On September 1, 2020, NHF and HFA learned that  Mylan N.V. is conducting a voluntary nationwide recall of  four lots of Tranexamic Acid Injection,…

The National Hemophilia Foundation (NHF) has received a five-year cooperative agreement from the Centers from Disease Control and Prevention (CDC). The collaboration,…